Australian company Telix has announced that the first patient has been dosed in a Phase 1 study of its investigational targeted radiation therapy, TLX250, combined with Merck's DNA-dependent protein kinase inhibitor candidate, peposertib. …
First patient dosed in study of Telix's TLX250 with Merck's peposertib
July 19, 2023 Australian Biotech
Latest Video
New Stories
-
Todd Stephenson confirmed on ACT list for New Zealand election
September 14, 2026 - - Latest News -
Scandal-hit KPMG still holds $37 million in health department work
September 14, 2026 - - Latest News -
Canberra details tax changes with limited concessions for some innovators
September 14, 2026 - - Latest News -
The 'Dispatched' Week in Review Podcast - 11 September
September 11, 2026 - - Podcast -
Rare genetic motor neurone disease treatment finally reaches Australian patients
September 11, 2026 - - Latest News -
NSW pharmacists to deliver all childhood vaccines and treat more conditions under reforms
September 11, 2026 - - Latest News -
AI Health Summit 2026
September 10, 2026 - - Summit